PDZ-RhoGEF, LARG, and p115RhoGEF are members of a newly identified family of Rho-guanine nucleotide exchange factors (GEFs) exhibiting a unique structural feature consisting of the presence of an area of similarity to regulators of G protein signaling (RGS). This RGS-like (RGL) domain provides a functional motif by which Ga 12 and Ga 13 can bind and regulate the activity of these RhoGEFs, thus providing a direct link from these heterotrimeric G proteins to Rho. PDZ-RhoGEF and LARG can also be phosphorylated by tyrosine kinases, including FAK, and associate with Plexin B, a semaphorin receptor, which controls axon guidance during development, through their PDZ domain, thereby stimulating Rho. Interestingly, while characterizing a PDZ-RhoGEF antiserum, we found that a transfected PDZ-RhoGEF construct associated with the endogenous PDZ-RhoGEF. Indeed, we observed that PDZ-RhoGEF and LARG can form homo-and hetero-oligomers, whereas p115RhoGEF can only homo-oligomerize, and that this intermolecular interaction was mediated by their unique C-terminal regions. Deletion of the C-terminal tail of PDZ-RhoGEF had no significant effect on the GEF catalytic activity towards Rho in vitro, but resulted in a drastic increase in the ability to stimulate a serum response element reporter and the accumulation of the GTP-bound Rho in vivo. Furthermore, removal of the C-termini of each of the three RGL-containing GEFs unleashed their full transforming potential. Together, these findings suggest the existence of a novel mechanism controlling the activity of PDZRhoGEF, LARG, and p115RhoGEF, which involves homo-and hetero-oligomerization through their inhibitory C-terminal region.
Introduction
The Rho family of GTPases, which includes Rho, Rac, and Cdc42, plays an important role in controlling the organization and dynamic remodeling of the actin-based cytoskeleton and in the regulation of gene expression. For example, when microinjected into Swiss 3T3 fibroblasts, activated Rho rapidly induces the formation of actin stress fibers and focal contacts (Ridley and Hall, 1992) , and activated alleles of Rho induce gene expression from the serum response element (SRE) through the activation of the serum response factor (SRF) (Hill et al., 1995) . Furthermore, Rho proteins also play a key role in a number of cellular processes that involve intracellular membrane trafficking, such as phagocytosis, endocytosis, and secretory vesicle transport (Takai et al., 2001) .
The functional activity of Rho is controlled by the combined activities of guanine nucleotide exchange factors (GEFs), GDP-dissociation inhibitors (GDIs) and GTPase activating proteins (GAPs) that act as positive or negative regulators of Rho-like proteins. Most GEFs for Rho GTPases include a highly conserved structural motif consisting of a 250-aminoacid stretch of sequence similarity with Dbl, known as Dbl homology (DH) domain, adjacent to a pleckstrin homology (PH) domain (Whitehead et al., 1997; Schmidt and Hall, 2002) . In vivo, the DH domain interacts with the inactive, GDP-bound GTPases and promotes the release of GDP and its subsequent exchange for GTP, thereby activating Rho proteins. The GEF activity of Dbl family members, such as Dbl, Ost, Lfc, Lbc, Vav, Ect2, Tim, and Net, can be activated upon stimulation of a number of cell surface receptors, including growth factor receptors, cytokine receptors, and cell to cell or cell to extracellular matrix adhesion molecules, thus acting as part of a signaling route by which extracellular stimuli can regulate the activity of Rho GTPases (Zheng, 2001; Schmidt and Hall, 2002) .
Available evidence indicates that a recently described family of DH domain-containing proteins that includes p115RhoGEF, PDZ-RhoGEF (PRG), and LARG can transduce signals from receptors coupled to the heterotrimeric G proteins G 12 and G 13 to Rho Fukuhara et al., 1999 Fukuhara et al., , 2000 . These three GEFs contain an area of limited similarity to a conserved region of regulator of G protein signaling (RGS) in their N-terminal region (Fukuhara et al., 2001; Longenecker et al., 2001) . RGS proteins function as GAPs for G proteins enhancing their rate of GTP hydrolysis. Indeed, the RGS-like (RGL) domain of p115RhoGEF can accelerate the GTPase activity of G 12/13 . In addition to this regulatory activity, the RGL domain of these RhoGEFs provides a structural motif by which G 12/13 proteins can form molecular complexes with these RhoGEFs, thereby enhancing their activity Fukuhara et al., 1999 Fukuhara et al., , 2000 . Thus, this newly discovered family of RGL-domain containing RhoGEFs, p115RhoGEF, PRG, and LARG provide a direct functional link from G 12 , G 13 , and their coupled cell surface receptors to Rho (Fukuhara et al., 2001) .
However, the nature of the molecular mechanisms controlling the activity of these Rho-GEFs is yet not fully understood. For example, recently reported evidence indicates that two of these RGL-containing RhoGEFs, PRG and LARG, can be phosphorylated in tyrosine residues by FAK in response to agonist stimulating G proteins , and that these RhoGEFs can associate through their PDZ domain to insulin-like growth factor receptors (Taya et al., 2001) and Plexin B (Aurandt et al., 2002; Perrot et al., 2002; Swiercz et al., 2002) , the latter a semaphorin receptor which controls axon guidance during development. Additionally, G 12/13 binding to the RGL domain of p115RhoGEF was shown to partially activate its GEF activity towards Rho, suggesting that the Nterminus of p115RhoGEF may impose an autoinhibition on the DH/PH module . However, whether the latter is indeed the case still remains unclear.
In this study, we observed that the RGL-containing RhoGEFs, PRG, LARG, and p115 RhoGEF, oligomerize through their C-termini. Furthermore, we found that PRG and LARG can also form heteromolecular complexes, while p115RhoGEF can only associate with itself but not with PRG or LARG. We also present evidence that although the C-terminal region has no detectable effect on the catalytic GEF activity in vitro, removal of the C-terminus of these RGL-containing RhoGEFs results in a remarkable increase in their ability to induce RhoA activation in vivo. Furthermore, deletion of the C-terminal region increases their ability to induce Rhodependent transcriptional responses and promotes neoplastic transformation. Thus, the C-terminus of the RGL-containing RhoGEFs may act as a negative regulatory region by which these GEFs can homo-or hetero-oligomerize and recruit additional cellular factors to modulate their Rho activating potential in cells.
Results
To begin exploring the molecular mechanisms regulating the activity of PRG, we developed a PRG antiserum against a C-terminal peptide, and characterized it upon expression of PRG in Human kidney 293T (HEK-293T) cells. As shown in Figure 1a , the PRG antibody recognized PRG but not other AU1-tagged members of the RGL-containing RhoGEF family, LARG and p115RhoGEF, which were readily detected by an antiepitope antibody. Furthermore, this antiserum immunoprecipitated endogenous as well as transfected PRG, and its specificity was confirmed by preincubating the antiserum with the peptide that was used as an immunogen ( Figure 1b) . As expected, this antibody recognized a HA tagged C-terminal fragment of PRG, but failed to detect a PRG C-terminal deletion mutant (Figure 1c) . Surprisingly, we observed that the transfected PRG full length and its C-terminus coimmunoprecipitated with the endogenous PRG (Figure 1c) , thus suggesting that PRG may form oligomeric molecular complexes.
To address which structural domain participates in the oligomerization of PRG, we expressed a N-terminal GFP-tagged PRG together with a number of deletion mutants, lacking parts of its N-terminus (-127, 238, 702, -958) , its C terminus (-C), or its catalytic region (-DH/ PH, -PH), or containing only some of its functional domains (PDZ/RGS, DH/PH, and PDG-C terminus) (Figure 2a ). The expression of GFP-PRG and the AU1-or HA-tagged PRG constructs in HEK-293T was confirmed using the corresponding anti-tag antibodies. As shown in Figure 2a , GFP-PRG coimmunoprecipitated with wild-type PRG and each of its mutants, as long as they included the C-terminal region of PRG, independently of the presence or absence of any other region or structural domain. In line with these observations, we found that when the C-terminal region of PRG was expressed as fusions of two different tags, HA and AU5, respectively, they form complexes that could be coimmunoprecipitated by either anti-tag antibody ( Figure 2b) . Thus, the C-terminal region of (amino acids 1181-1522) PRG is necessary and sufficient to promote the formation of oligomeric molecular complexes. The nature of the precise residues participating in this process is under current investigation. In this regard, the fact that the C-terminal PRG antibody does not prevent PRG oligomerization suggests that residues 1401-1414 and their adjacent region may not be critical for this interaction. Next, we asked whether other member of the RGLcontaining RhoGEFs would be able to form oligomers. For these experiments, we engineered AU1-tagged expression vectors for the full length, N-terminal deleted and C-terminal deleted forms of LARG and p115 RhoGEF, as well as an EGFP-tagged form of each of their full-length constructs. As shown in Figure 3 , all three RGL-containing RhoGEFs were able to homooligomerize, and this property was strictly dependent on the availability of their C-terminal regions.
We then explored whether these RhoGEFs could form hetero-oligomers. Surprisingly, PRG and LARG could hetero-oligomerize with each other, as judged by the ability to coimmunoprecipitate the GFP-tagged form of PRG and LARG with the AU1 tagged form of LARG and PRG, respectively. In contrast, p115 RhoGEF could only homo-oligomerize, as it did not associate with the other members of this RhoGEF family ( Figure 4a ). These observations were confirmed by coexpressing the GFP tagged GEFs with constructs expressing their C-termini. Indeed, as shown in Figure 4b , the isolated C-terminus of PRG associated with PRG and LARG but not p115 RhoGEF; the LARG C-terminus coimmunoprecipitated only with PRG and LARG; and the C-terminus of p115 RhoGEF associated exclusively with its full-length molecule. Together, these data indicate that PRG and LARG can homo-and hetero-oligomerize, while p115 RhoGEF can only associate through homophilic interactions. Lysates from transfected cells were immunoprecipitated with anti-AU5 antibody or anti-HA antibody, and subjected to Western blot (WB) analysis with each of these antibodies, as indicated. The corresponding total cellular lysates (TCL) were also subjected to Western blot analysis using anti-AU5 and anti-HA antibodies Figure 3 Homo-oligomerization of RGL-containing RhoGEFs. HEK-293T cells were transfected with expression plasmids for AU1 tagged forms of PRG, LARG, and p115 RhoGEF, either wild-type (wt) or their N-terminal (N) or C-terminal (C) deletion mutants, or empty vector (control), together with GFP tagged PRG, LARG, and p115 RhoGEF, as indicated. Lysates were immunoprecipitated with anti-AU1 antibodies and subjected to Western blot analysis with antibodies against GFP. TCL were also subjected to Western blot analysis using AU1 and GFP antibodies. Arrows indicate the corresponding AU1-tagged proteins
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To evaluate whether the oligomerization of these GEFs through their C-terminal region might modulate their catalytic GEF activity, we overexpressed a panel of PRG mutants as well as wild-type PRG in 293T cells as AU1-fusions and purified them to homogeneity by using anti-AU1 affinity chromatography (Figure 5a ). When equal molar quantities (0.2 mm) of the purified PRG, the C-terminal deletion mutant (PRG C), the N-terminal deletion mutant (PRG N), and the DH/PH module were examined in an in vitro GTP/GDP exchange reaction, we found that the removal of either N-or C-terminal region had a very minor effect, if any, on the PRG's ability to stimulate [ 3 H]GDP dissociation from RhoA ( Figure 5b ). Furthermore, they behaved similarly in altering the kinetics of GDP-dissociation of RhoA at increasing concentrations (data not shown). These results suggest that oligomerization by the C-terminal region of PRG does not affect the in vitro catalytic GEF activity of the DH/PH module. Moreover, the Nterminal RGL-domain also does not appear to directly impose a significant autoinhibition.
To assess the functional consequences of these findings in vivo, we next examined whether deletion of the C-terminal region of the GEFs, that prevents oligomerization, can affect their ability to stimulate Rho and Rho-downstream pathways in cellular systems. For the latter, we took advantage of the observation that RGL-containing RhoGEFs activate the transcriptional activity of the c-fos SRE (Fukuhara et al., 1999; Shi et al., 2000) . Indeed, all three members of this GEF family stimulated luciferase expression from the SRE Figure 4 Homo-and hetero-oligomerization of RGL-containing RhoGEFs. HEK-293T cells were transfected with expression plasmids for AU1-tagged PRG, LARG and p115 RhoGEF, or vector alone (Control) together with GFP-tagged forms of PRG, LARG, or p115 RhoGEF, as indicated. Cellular lysates were immunoprecipitated (IP) with anti-AU1 antibodies and subjected to Western blot analysis with antibodies against GFP. TCL were also subjected to Western blot analysis using anti-AU1 and anti-GFP antibodies (Panel a). HEK-293T cells were also transfected with expression plasmids for HA-tagged C-terminal region of PRG (PRG-C), LARG (LARG-C), and p115 RhoGEF (p115-C) together with GFP-tagged PRG, LARG, or p115 RhoGEF. Lysates were processed as for Panel a, but using an anti-HA antibody for immunoprecipitation and Western blot analysis reporter plasmid, as shown in Figure 6a . Interestingly, the C-terminal deletion mutants of PRG (PRG C), LARG (LARG C), and p115 (p115 C) stimulated the SRE activity much more potently than their corresponding wild-type molecules (Figure 6a ). In line with this observation, the ability of these C-terminal deletion mutants to promote the accumulation of endogenous RhoA in its GTP-bound active state was also dramatically increased when compared to that of the corresponding wild types (Figure 6b ). These findings indicate that the C-terminal regions of RGL-containing RhoGEFs, which participate in the formation of oligomeric complexes, can limit the activity of these GEFs in vivo and display an inhibitory effect. Activated RhoA (RhoA QL) induces the appearance of transformed foci when expressed in NIH 3T3 cells (Zohar et al., 1998) . In line with this observation, we have recently shown that PRG, LARG, and p115Rho-GEF harbor transforming potential (Fukuhara et al., 2001) . Of interest, while PRG induced the appearance of Rho-like foci when transfected in NIH 3T3 cells, deletion of its C-terminal region enhanced its focus forming activity by more than twofold, which was now comparable to the potency exhibited by the active form of RhoA (Figure 7, Table 1) . Similarly, C-terminal deletion dramatically increased the transforming potential of LARG and p115 Rho GEF (Table 1) , which is consistent with the transcriptional and in vivo Rhoactivating data, thus supporting the biological relevance of the negative regulatory activity exerted by the Cterminal region of the RGL-containing Rho GEFs. Figure 6 Activation of RGL-containing RhoGEF by deletion of their C-terminal region. HEK-293T cells were transfected with pSRE Luc together with expression plasmids for PRG, LARG, p115 RhoGEF, or their respective C-terminal deletion mutants (C). Cells were serum starved, and lysates processed for Luciferase assay as described under 'Experimental procedures.' The data represent Luc activity are the mean 7s.e. of triplicate samples from a typical experiment, which was repeated three times with nearly identical results (Panel a). Parallel samples excluding the reporter construct were incubated with GST-RBD beads to affinity precipitate GTP-bound Rho. The beads were washed and the total amount of Rho in each cell lysate (total Rho) and Rho bound to the beads (GTP-Rho) was analysed by Western blotting with a monoclonal antibody against RhoA (Panel b) Figure 7 Oncogenic activation of PRG by C-terminal deletion. NIH 3T3 cells were transfected with empty vector (control) or an expression plasmid for activated RhoA (RhoA QL) (1 mg per plate), PRG (1 mg per plate), PRG C (1 mg per plate), LARG (1 mg per plate), LARG C (1 mg per plate), p115 RhoGEF (1 mg per plate), and p115 RhoGEF C (1 mg per plate). Cells were stained 3 weeks after transfection. Representative plates are depicted. Foci of transformation were counted in triplicate plates in independent transfections, and the number of foci per g of transfected DNA for each construct is documented in (Fukuhara et al., 2001) . These RhoGEFs can be further regulated by tyrosine phosphorylation , and two of these GEFs, PRG and LARG, can be activated through the association of their PDZ domains with insulin-like growth factor receptor or the cytoplasmic tail of Plexin B (Taya et al., 2001; Aurandt et al., 2002; Perrot et al., 2002; Swiercz et al., 2002) . During the course of characterizing a PRG-specific antiserum, we discovered that this GEF can form oligomers through its C-terminal region. Similar behavior was observed for LARG and p115 RhoGEF. PRG and LARG, but not p115 RhoGEF, were also found to hetero-oligomerize. Interestingly, deletion of the Cterminal region did not affect the GEF activity of PRG in vitro, but deletion of this region prevented the formation of homo-or hetero-oligomeric molecular complexes. It also resulted in the enhanced GEF activity of PRG, LARG, and p115RhoGEF in vivo and unleashed the full transforming potential of these GEFs. Thus, this family of RhoGEF may also share the presence of an inhibitory C-terminal region by which they can form oligomeric molecular complexes and likely recruit inhibitory factors in cells. The use of intra-and intermolecular interactions as a mechanism for regulating molecular activity is widespread in biological system. Recent accumulating evidence suggests that these mechanisms, which include protein-protein and protein-lipid interactions, may provide the bases for a regulatory network controlling the activity of the Dbl family of RhoGEFs (reviewed in Zheng (2001) . Among them, perhaps the best understood mechanisms are those controlling the conformation and/or localization of the DH-PH domains or their accessibility to bind and stimulate nucleotide exchange on Rho GTPases. This process is best illustrated by Vav1, whose activity is tightly controlled by tyrosine phosphorylation (Crespo et al., 1997; Teramoto et al., 1997) . For example, Vav1 is phosphorylated in Tyr174 by Src family tyrosine kinases after cytokine or adhesion receptor activation, and this phosphorylation leads to its activation (Bustelo, 2000) . Structural analysis revealed that Tyr174 lies at the center of an inhibitory helix that binds a complementary cleft on a conserved face of the DH domain, thus hindering the access to its GTPasebinding site. Phosphorylation of this tyrosine affects the intramolecular binding interfase, as well as destabilizes the helical structure of this inhibitory region, both contributing to the release of the auto-inhibitory interaction, which results in the upregulation of the GEF activity of Vav1 (Aghazadeh et al., 2000) . In the case of proto-Dbl, intermolecular interactions between its N terminus and the PH domain maintains it in an auto-inhibited, inactive state, by limiting the access of RhoA and Cdc42 to the catalytic site of the DH domain (Aghazadeh et al., 2000) . The DH-PH domain of Vav, as well as that of Sos1, can also be regulated through the interaction of phospholipids with the PH domain. For example, the PI3K product phosphoinositol (3, 4, 5) trisphosphate binds to their PH domain and appears to alleviate an inhibitory effect of the PH domain on the DH domain (Han et al., 1998; Nimnual et al., 1998) . By contrast, the GEF activity of Dbl towards Cdc42 was found to be inhibited by either phosphoinositol (4, 5) diphosphate or phospohoinositol (3, 4, 5) trisphosphate binding to the PH domain (Russo et al., 2001) . These findings suggest that phosphatidylinositol phospholipids can regulate, either in a positive or negative fashion, the intramolecular interaction between the DH and PH domains.
In addition to intramolecular interactions and their regulation by phosphorylation or lipid binding, many Rho GEFs exhibit a number of conserved structural domains that are also present in other signal transducing molecules, which enable regulatory interactions that ultimately modulate the GEF activity of the DH domain (Cerione and Zheng, 1996) . One example is Tiam1, which was recently found to contain a Ras-binding domain (Ponting, 1999) and therefore activates Rac1 in response to Ras stimulation (Lambert et al., 2002) . That also includes the regulation of p115RhoGEF, PRG, and LARG by G 13 through their RGL domain, presumably by releasing an inhibitory constraint on the DH domain . However, the fact that deletion of the N-terminal PDZ and RGL domains from PRG does not appear to affect the GEF catalytic activity as assayed in a purified system suggests that the N-terminus does not constitute an autoinhibitory region, and that the regulatory binding to the N-terminus by G 13 , for example, may not be per se sufficient to regulate their GEF catalytic function. Our recent observations that palmitoylation-deficient G 12 and G 13 bind PRG but fail to promote Rho activation in vivo (JSG, unpublished results) further suggest that the G 12/13 interaction with PDZ-RhoGEF may serve as a targeting signal for the effective regulation of the GEF function.
Interestingly, we now show that RGL-containing RhoGEFs can form oligomers by intermolecular interactions through their inhibitory C-terminal domain, which may thereby regulate their activity in vivo. Similar to this observation, Kim et al. have shown that the Cdc42/Rac1 GEF, p21-activated kinase interacting factor PIX, uses its C-terminal end to form homodimers in vitro and in vivo through a leucine zipper domain (Kim et al., 2001) . Deletion of the leucine zipper domain and the resulting loss of homo-oligomerization prevented, rather than stimulating, Pix function in vivo (Kim et al., 2001) . In other cases, oligomerization has also been reported to occur through DH-DH domain interactions, such as for RasGRF1, RasGRF2, and Dbl (Anborgh et al., 1999; Zhu et al., 2001) . In these cases, inhibition of oligomerization diminishes the in vivo GEF activity of Dbl for Cdc42 and Rho, and that of RasGEF1 and RasGEF2 for Ras. Thus, distinct GEFs can use conserved regulatory domains to promote their oligomerization, and the ability to form oligomers may serve as an important mode of regulation in vivo.
In contrast to PIX, Dbl, RasGEF1, and RasGEF2, no distinguishable conserved domains are present in the C-terminal region of PRG, LARG, and p115 RhoGEF, other than a predictable coiled-coiled structure for p115RhoGEF but not for PRG and LARG (J Sondek, personal communication). Indeed, their C-termini are quite distinct, and are one of the most divergent regions among these three otherwise related GEFs. In addition, the C-terminal-mediated oligomerization of RGL-containing RhoGEFs is inhibitory in nature, rather than required for Rho activation. In turn, how the C-terminal oligomerization inhibits the function of these RhoGEFs is still unknown. Our findings suggest that the Cterminal region does not bind the DH-PH domain or any other N-terminal regulatory region. In line with these observations, coexpression of the isolated Cterminus does not inhibit the in vivo GEF activity of p115RhoGEF, PRG or LARG, or their C-terminal deletion mutants (not shown). In addition, binding of G 13 to their RGL domain does not disrupt their oligomerization, nor the absence of the C-terminal region affects the overall cellular distribution of these GEFs, which is primarily cytoplasmic (unpublished observations). However, whether C-terminal deletion promotes the localization of these GEFs to a particular subcellular fraction or membrane microdomain, or its enhanced colocalization with Rho warrants further investigation. On the other hand, the clear difference in Rho-activating potential of the full-length PRG and the C-terminal deleted PRG in vivo suggests that the Cterminal region of this GEF may interact with yet to be identified negative regulatory molecules that can be brought into close proximity to the catalytic DH-PH domain by virtue of this interaction.
We can conclude that the recently described family of RGL-containing RhoGEFs shares the presence of a functionally but not structurally related C-terminal region. The function of this region appears to be complex, as it participates in homo-or hetero-oligomerization and may also recruit additional cellular factors resulting in the downregulation of their GEF activity in vivo. These findings provide a likely mechanism by which the activity of these GEFs is restricted under basal conditions, thus preventing the manifestation of their Rho-activating and oncogenic potential. They also raise the possibility of the existence of both positive and negative pathways that may control the activity of this GEF family by acting on their inhibitory C-termini or through the regulation of their oligomeric state.
Materials and methods

Expression plasmids
Plasmids expressing AU1-tagged PRG (amino acids 1-1522), LARG (amino acids 1-1544), p115RhoGEF (amino acids 1-912) and deletion mutant forms of PRG (-127-238-702-956 -DH/PH, -PH), and cDNAs encoding amino acids 1-1160 of PRG (-C), 1-702 of PRG (PDZ/RGS), 702-1160 of PRG (DH/PH), AU5-tagged RhoA QL, as well as the pSRE Luc reporter plasmid were described previously (Zohar et al., 1998; Fukuhara et al., 1999 Fukuhara et al., , 2000 Chikumi et al., 2002) . C-terminal HA-tagged or AU5-tagged forms of C-terminal region of PRG (amino acids 1181-1522), LARG (amino acids 1141-1544) and p115 (amino acids 771-912), AU1-tagged LARG -C (amino acids 1-1160), and p115 RhoGEF-C (amino acids 1-800), as well as AU-1 tagged PRG -N (amino acids 702-1522), LARG -N (amino acids 641-1544), and p115RhoGEF -N (amino acids 351-912) were generated by polymerase chain reaction using their corresponding cDNAs as a template. pGEX expression vector encoding glutathione S-transferase (GST) fusion protein that contains the isolated GTP-dependent binding domain of the RhoA effector rhotekin (rhotekin RBD) was provided by Dr S Narumiya (Reid et al., 1996) .
Cell lines and transfection
HEK-293T cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Tissue culture plates were treated with phosphate buffered saline (PBS) containing 20 mg/ml poly-d-lysine for 15 min before seeding the cells, to prevent them from detaching from the plates when in serum-free conditions. Cells were transfected using LipofectAMINE Plus TM reagent (Life Technologies, Inc.) according to the manufacturer's protocol.
Reporter gene assay
The SRE activity was determined as described previously (Sakabe et al., 2002) . Briefly, HEK-293T cells plated in a sixwell plate together with 0.1 mg of pSRE Luc reporter plasmid. After overnight incubation, the cells were washed with serumfree DMEM, and kept for 24 h in DMEM supplemented with 20 mm HEPES. Cells were then lysed using reporter lysis buffer (Promega).
Western blots and immunoprecipitations
Cells were lysed at 41C in a buffer containing 25 mm HEPES, pH 7.5, 0.3 M NaCl, 1.5 mm MgCl 2 , 0.2 mm EDTA, 0.5 mm dithiothreitol (DTT), 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 20 mm b-glycerophosphate, 1 mm sodium vanadate, 1 mm phenylmethylsulfonyl fluoride, 20 mg/ml aprotinin, and 20 mg/ml leupeptinin, and insoluble material was removed by centrifugation. For coimmunoprecipitation, lysates were incubated with for 1 h at 41C with the specific antibody against AU1, HA, or AU5, as indicated. Immunocomplexes were recovered with the aid of Gamma-bound Sepharose beads (Pharmacia). Lysates containing approximately 50 g of total cellular protein or immunoprecipitates with the indicated antibodies were analysed by Western blotting after SDS-polyacrylamide gel electrophoresis and visualized by enhanced chemiluminescence detection (Amersham Pharmacia Biotech) using goat anti-mouse (Cappel or goat anti-rabbit (Cappel) IgGs coupled to horseradish peroxidase as a secondary antibody. C-terminal of Anti-PRG serum was raised in rabbits against a C-terminal polypeptide corresponding to amino acids 1401-1414 of human PRG (NP_055599). Antibodies against RhoA (26C4) were purchased from Santa Cruz Biotechnology. Monoclonal antibody against HA, AU1, and AU5 epitope was purchased form COVANCE.
In vitro GDP/GTP exchange assay
The time courses for [ 3 H]GDP/GTP exchange of Rho GTPase in the presence or absence of PRG and its mutants were Regulation of RGL-containing RhoGEFs H Chikumi et al determined as previously described using the nitrocellulose filtration method (Hart et al., 1994) . The GEF reaction buffer contains [ 3 H]GDP-loaded RhoA (1 mm) with 20 mm Tris-HCl, pH 7.6, 100 mm NaCl, 10 mm MgCl 2 , 0.5 mm GTP, and 1 mm DTT supplemented with the indicated amounts of purified PRG or its mutants. The reactions were terminated at the indicated time points, and the percentages of remaining RhoA bound [
3 H]GDP were quantified.
In vivo Rho guanine nucleotide exchange assay
In vivo Rho activity was assessed by a modified method described elsewhere (Ren et al., 1999) . Briefly, HEK-293T cells were transfected with the indicated plasmids. After serum starvation for 24 h, cells were lysed at 41C in a buffer containing 20 mm HEPES, pH 7.4, 0.1 m NaCl, 1% Triton X-100, 10 mm EGTA, 40 mm b-glycerophosphate, 20 mm MgCl 2 , 1 mm Na 3 VO 4 , 1 mm DTT, 10 mg/ml aprotinin, 10 mg/ ml leupeptin, and 1 mm phenylmethylsulfonyl fluoride. Lysates were incubated with GST fusion protein including the Rhobinding domain (RBD) of rhotekin previously bound to glutathione-Sepharose beads, followed by four washes with lysis buffer. GTP-bound forms of Rho associated with GSTrhotekin-RBD were released from beads by addition of protein loading buffer, and quantified by Western blot analysis using a monoclonal antibody against RhoA (26C4) (Santa Cruz Biotechnology).
Foci formation in NIH3T3 cells
Plasmid DNA transfection of NIH 3T3 cells was performed by the calcium phosphate precipitation technique, and transformed foci were scored after 2-3 weeks as described (Zohar et al., 1998) .
